{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:00:47Z","timestamp":1792814447217,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bausch Health Companies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s13555-025-01497-w","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T16:28:48Z","timestamp":1753806528000},"page":"3025-3035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Brodalumab: Seven-Year US Pharmacovigilance Report"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1005-5221","authenticated-orcid":false,"given":"John Y.","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-6286","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-2057","authenticated-orcid":false,"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3685-668X","authenticated-orcid":false,"given":"Soo Han","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7856-6615","authenticated-orcid":false,"given":"Nicole N.","family":"Rawnsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3935-8355","authenticated-orcid":false,"given":"Earl L.","family":"Goehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-2280","authenticated-orcid":false,"given":"Abby A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1497_CR1","unstructured":"Siliq [package insert]. Bridgewater, NJ: Bausch Health Companies Inc; 2024."},{"issue":"13","key":"1497_CR2","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.3390\/ijms22136740","volume":"22","author":"S Vidal","year":"2021","unstructured":"Vidal S, Puig L, Carrascosa-Carrillo JM, Gonzalez-Cantero A, Ruiz-Carrascosa JC, Velasco-Pastor AM. From messengers to receptors in psoriasis: the role of IL-17RA in disease and treatment. Int J Mol Sci. 2021;22(13):6740.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1497_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/bjd.20090","volume":"185","author":"MAX Tollenaere","year":"2021","unstructured":"Tollenaere MAX, Hebsgaard J, Ewald DA, et al. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor\u00a0A drives psoriasis-related inflammatory pathways. Br J Dermatol. 2021;185(3):585\u201394.","journal-title":"Br J Dermatol"},{"issue":"8","key":"1497_CR4","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","volume":"192","author":"CB Russell","year":"2014","unstructured":"Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828\u201336.","journal-title":"J Immunol"},{"issue":"6","key":"1497_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1111\/bjd.19132","volume":"183","author":"K Papp","year":"2020","unstructured":"Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120\u00a0weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase\u00a0III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037\u201348.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1497_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase\u00a0III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1497_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","volume":"82","author":"L Puig","year":"2020","unstructured":"Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase\u00a03 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"1497_CR8","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","volume":"366","author":"KA Papp","year":"2012","unstructured":"Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181\u20139.","journal-title":"N Engl J Med"},{"issue":"14","key":"1497_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase\u00a03 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"8","key":"1497_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.36849\/JDD.2020.5138","volume":"19","author":"M Lebwohl","year":"2020","unstructured":"Lebwohl M, Leonardi C, Wu JJ, et al. One-year pharmacovigilance update of brodalumab. J Drugs Dermatol. 2020;19(8):807\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"1497_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-020-00472-x","volume":"11","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Leonardi C, Wu JJ, et al. Two-year US pharmacovigilance report on brodalumab. Dermatol Ther (Heidelb). 2021;11(1):173\u201380.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1497_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15105","volume":"34","author":"M Lebwohl","year":"2021","unstructured":"Lebwohl M, Leonardi C, Armstrong A, et al. Three-year U.S. pharmacovigilance report of brodalumab. Dermatol Ther. 2021;34(6):e15105.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1497_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.36849\/JDD.7344","volume":"22","author":"M Lebwohl","year":"2023","unstructured":"Lebwohl M, Koo J, Leonardi C, et al. Brodalumab: 4-year US pharmacovigilance report. J Drugs Dermatol. 2023;22(4):419\u201322.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"1497_CR14","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s13555-024-01162-8","volume":"14","author":"MG Lebwohl","year":"2024","unstructured":"Lebwohl MG, Koo JY, Armstrong AW, et al. Brodalumab: 5-year US pharmacovigilance report. Dermatol Ther (Heidelb). 2024;14(5):1349\u201357.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1497_CR15","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s13555-024-01304-y","volume":"15","author":"MG Lebwohl","year":"2025","unstructured":"Lebwohl MG, Koo JY, Armstrong AW, et al. Brodalumab: Six-year US pharmacovigilance report. Dermatol Ther (Heidelb). 2025;15(1):213\u201322.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1497_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","volume":"78","author":"MG Lebwohl","year":"2018","unstructured":"Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81-9.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"1497_CR17","first-page":"1441","volume":"13","author":"AB Gottlieb","year":"2014","unstructured":"Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12):1441\u20138.","journal-title":"J Drugs Dermatol"},{"key":"1497_CR18","doi-asserted-by":"publisher","first-page":"204209862211250","DOI":"10.1177\/20420986221125006","volume":"13","author":"S Lucas","year":"2022","unstructured":"Lucas S, Ailani J, Smith TR, Abdrabboh A, Xue F, Navetta MS. Pharmacovigilance: reporting requirements throughout a product\u2019s lifecycle. Ther Adv Drug Saf. 2022;13:20420986221125010.","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"1497_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jid.2018.07.029","volume":"139","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP, Burisch J, Colombel JF. Incidence and risk of inflammatory bowel disease in patients with psoriasis-a nationwide 20-year cohort study. J Invest Dermatol. 2019;139(2):316\u201323.","journal-title":"J Invest Dermatol"},{"key":"1497_CR20","doi-asserted-by":"crossref","unstructured":"Kimmel G, Lebwohl M, Gordon K, von Csiky-Sessoms S, Cronin A, Jacobson A. Real-world disease severity of patients with psoriasis initiating brodalumab: findings from the Corrona Psoriasis Registry. In: Slides presented at: 78th Annual Meeting of the American Academy of Dermatology; March 20\u201324, 2020; Denver, CO.","DOI":"10.1016\/j.jaad.2020.06.812"},{"key":"1497_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jdin.2022.08.010","volume":"9","author":"S Yeroushalmi","year":"2022","unstructured":"Yeroushalmi S, Chung M, Bartholomew E, Hakimi M, Koo J. Examining worldwide postmarketing suicides from biologics used for psoriasis with a focus on brodalumab: a cross-sectional analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). JAAD Int. 2022;9:119\u201321.","journal-title":"JAAD Int"},{"issue":"1","key":"1497_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40257-017-0328-3","volume":"19","author":"M Amin","year":"2018","unstructured":"Amin M, No DJ, Egeberg A, Wu JJ. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2018;19(1):1\u201313.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1497_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01497-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01497-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01497-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T13:13:05Z","timestamp":1758719585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01497-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1497"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01497-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"24 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark G. Lebwohl is an Editorial Board member of\n                      Dermatology and Therapy\n                      and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions; is an employee of Mount Sinai; receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy Dermatology, Strata, Takeda, Trevi Therapeutics, and Verrica. John Y. Koo has been a consultant or speaker for AbbVie, Amgen, Eli Lilly, EPI, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and Sun Pharmaceutical. April W. Armstrong has served as a research investigator for and\/or scientific advisor to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dermira, Eli Lilly, EPI, Incyte, Janssen, LEO Pharma, Mindera, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical, and UCB. Bruce E. Strober has been an investigator, scientific director, consultant, or member of a speakers bureau or advisory board for AbbVie, Acelyrin, Alamar, Almirall, Alumis, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol-Myers Squibb, Capital One, Celltrion, CorEvitas and the CorEvitas Psoriasis Patient Registry, Dermavant, Eli Lilly, Incyte, Inmagene Bio, Janssen, Kangpu Pharmaceuticals, LEO Pharma, Maruho, Meiji Seika Pharma, Monte Carlo, Novartis, Okura, Pfizer, Protagonist, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, Takeda, UCB Pharma, and Union Therapeutics; holds stock options in Connect Biopharma and Mindera Health; and serves as the editor-in-chief of the\n                      Journal of Psoriasis and Psoriatic Arthritis\n                      . Soo Han Yoon is an employee of Salix Pharmaceuticals. Nicole N. Rawnsley, Earl L. Goehring Jr, and Abby A. Jacobson are employees of Bausch Health Companies Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Postmarket monitoring of safety data by drug manufacturers is mandated by the FDA, and ethics committee approval for such monitoring is not required. All data were nonidentifiable and informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}